Pulmatrix (NASDAQ:PULM) Posts Earnings Results, Beats Expectations By $1.66 EPS

Pulmatrix (NASDAQ:PULM – Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.00) by $1.66, FiscalAI reports.

Pulmatrix Price Performance

Shares of PULM traded up $0.09 on Monday, hitting $1.38. The company’s stock had a trading volume of 18,417 shares, compared to its average volume of 39,731. Pulmatrix has a fifty-two week low of $1.06 and a fifty-two week high of $4.98. The company has a market capitalization of $5.04 million, a PE ratio of -1.25 and a beta of 1.95. The company has a 50 day moving average price of $1.46 and a 200 day moving average price of $1.66.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmatrix in a research note on Thursday. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Get Our Latest Stock Report on PULM

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies. Its proprietary iSPERSE technology is designed to deliver dry-powder medicines to the lungs, and the company’s work has included treatments for respiratory diseases as well as medicines delivered through the lungs for other conditions. Among its drug candidates, PUR1900 is an inhaled formulation of itraconazole being developed for allergic bronchopulmonary aspergillosis, a lung condition associated with fungal sensitivity.

Read More

Earnings History for Pulmatrix (NASDAQ:PULM)

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.